Iofina plc provided earnings guidance for the full year of 2013. The company's revenue is likely to be comparable to 2012 levels. This is due to expected 2013 shipments at Iofina Chemical now being delayed into 2014.

External iodine sales which were previously expected in 2013 are now expected to commence in 2014, resulting in an inventory build-up. To the extent that iodine produced by the Group is used in the production of iodine derivatives and not sold outside the Group, the value of such iodine production is a component of the derivatives revenue at Iofina Chemical and will not appear as raw iodine revenue from Iofina Resources. The Group's overall margins benefit from using iodine produced at Iofina Resources, due to its advantageous production cost.

Considering the lower revenue expectations, EBITDA excluding share option charges, will likely be similar to 2012 levels. The company expects revenues and EBITDA to be comparable to 2012, 2013 has seen the successful deployment of Iofina's IOsorb technology along with the continued growth of its derivatives business.